Drugs / Florajen Digestion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04721912 | Dec 2020 → Aug 2023 | group B streptococcal infection | University of New Mexico | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Florajen Digestion | “An open-label randomized clinical trial comparing Florajen Digestion, a commercially available combination oral probiotic, with usual care” PMID 40442923 ↗ May 20251“Florajen Digestion™” NCT04721912 ↗ |
| Modality | Other / unclassified | “Florajen Digestion, a commercially available combination oral probiotic” PMID 40442923 ↗ May 2025 |
| Route | Oral | “will begin taking oral Florajen Digestion probiotic capsules once daily” NCT04721912 ↗ |